Autopsy report · NCT01693653

Tocilizumab for the Treatment of Behcet's Syndrome

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“low enrollment”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 2 months before it stopped.
1 participant enrolled.
Results were posted on the registry 2 years 7 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: NYU Langone Health
Sponsor type: University, hospital or other
Conditions: Behcet Syndrome
Interventions: Tocilizumab
Participants: 1
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.